GMP IPO Watch
GSP Crop Science IPO Day 2: QIBs Lead the Charge While Retail Stays Cautious
Ahmedabad-based GSP Crop Science is currently in the middle of its ₹400 crore mainboard IPO (March 16–18, 2026). While the issue saw a solid 47% subscription on its opening day—driven primarily by institutional interest—the grey market remains flat. We break down the Day 2 pulse, the 18x valuation, and whether the debt-reduction strategy makes it a long-term winner.
Live IPO tracking available
Check GMP movement, allotment details, subscription demand, and deeper IPO context for this company.
Use these shortcuts to keep exploring
The archive button opens all articles from this category. The IPO details button opens the live IPO page on your GMP site in a new tab.
1. The Business: 40 Years of "Make in India" Agrochemicals
GSP Crop Science is a veteran in the field, operating since 1985. They aren't just manufacturers; they are a research-heavy powerhouse focused on crop protection:
Massive Portfolio: They hold 524 product registrations across insecticides, herbicides, and fungicides.
Intellectual Property: With 102 patents granted and 108 more in the pipeline, they have a significant "moat" against generic competitors.
Global Footprint: Their products reach farmers in over 37 countries, including the USA, Brazil, and Australia.
2. IPO Timeline & Participation Details
The bidding is live right now and will close tomorrow. Here is the schedule:
| Event / Detail | Information |
|---|---|
| Bidding Period | March 16 – March 18, 2026 |
| Price Band | ₹304 to ₹320 per share |
| Minimum Lot Size | 46 Shares |
| Min. Retail Investment | ₹14,720 |
| Total Issue Size | ₹400 Crore (Fresh: ₹240 Cr |
| Listing Date | Tuesday, March 24, 2026 (NSE & BSE) |
3. Live Subscription Pulse (Day 2 Status)
The "smart money" moved in early, but the retail crowd is still watching from the sidelines.
Qualified Institutional Buyers (QIBs): Already 1.28x subscribed. This is a strong signal that professional fund managers like the company’s fundamentals.
Non-Institutional Investors (NII/HNI): 28% subscribed.
Retail Individual Investors: 11% subscribed.
Grey Market Premium (GMP): ₹0 (Flat).
What this means: The grey market isn't predicting a "listing pop." This is looking like a fundamental play for the long haul rather than a quick listing-day profit.
4. Financials: A Profit "U-Turn"
The company’s recent financial performance has been the highlight of its pitch:
Revenue Growth: Steady growth, reaching ₹1,301 crore in FY25.
Profit Explosion: PAT surged from ₹17.5 crore (FY23) to ₹81.4 crore (FY25).
H1 FY26 Momentum: In the first half of this fiscal year (Sept 2025), they have already earned ₹81 crore—meaning they are on track to potentially double last year's profits.
Valuation: At the ₹320 cap, the P/E ratio is ~15.3x, which many analysts consider "discounted" compared to peers like Sumitomo Chemical (39x).
5. Strategic Use of Funds: Clearing the Slate
A massive ₹170 crore of the fresh issue is being used to repay debt. By reducing their interest burden, the company will immediately improve its bottom line and free up cash for its heavy R&D cycle.
6. Investor Analysis: Pros & Cons
Strengths:
Deep Discount: Priced lower than many of its listed peers, offering a potential "value" entry.
Patent Moat: Their focus on R&D protects them from the price wars common in the generic chemical market.
Export Diversification: Revenue is balanced between India and global markets, reducing risk from a single bad monsoon.
Risks:
Flat GMP: If you are looking for 50% gains on listing day, this IPO might disappoint.
Working Capital Needs: Agrochemicals is a cash-heavy business; despite the IPO, they will still carry some debt.
Regulatory Hurdles: Stringent environmental norms in Gujarat (where their units are based) require constant compliance.
7. Conclusion: The "Fundamental" Choice
GSP Crop Science is a 40-year-old story that is finally getting its moment on the big stage. While the ₹0 GMP suggests a flat listing, the strong QIB interest and cheap valuation make it a serious contender for long-term investors who believe in the "Make in India" agrochemical story.
